DarioHealth Corp. heads into the close of a pivotal week with the stock up nearly 9% — and fresh Q1 earnings beats adding momentum to what has already been a strong month.
Q1 results, reported this morning, delivered a double beat. Adjusted EPS came in at -$0.95 against a consensus estimate of -$1.48. Revenue of $5.58 million edged past the $5.48 million forecast. That follows the prior quarter's -10.5% one-day drop in March, which means this print lands against a low bar of sentiment. The call itself was substantive: CEO Erez Raphael announced that DarioHealth has entered the contracting stage with what he described as the largest channel partner in the company's history — a relationship stemming from a major Northeastern US hospital network, with access to roughly 65 million additional covered lives and around 3,500 employer relationships. Combined with existing partnerships through Solera and Amwell, that would push the company's distribution reach to over 175 million covered lives.
Positioning tells a broadly relaxed story, where shorts are stepping back rather than pressing. Short interest is running at just under 1% of the free float — not a level that generates meaningful squeeze pressure. More interesting is the trajectory: estimated short shares climbed sharply through late April, jumping from around 39,000 to over 70,000 in just a few sessions between April 22–27, before slowly unwinding over the past two weeks to roughly 67,000 today. That April build has been partially reversed, and the 4.6% week-on-week decline in short shares suggests some of that positioning was caught wrong-footed by the recent price recovery. Borrow costs are modest at around 4.9% APR — down meaningfully from roughly 6% in early April — and availability in the lending pool is loose, reflecting no material stress in the borrow market. The ORTEX short score of 45.9 is mid-range and drifting slightly lower, consistent with a stock where short pressure is not the dominant story.
Where the Street stands is worth noting with some caution. All three analyst ratings on file are buys, and the mean price target is $18.50, implying over 100% upside from the current $8.68 close. The sole recent analyst action on file is from Stifel in late March — a maintained Buy with a target cut from $16.00 to $10.00, following Q4 results that disappointed. That target is itself now above the current price, so analyst consensus remains constructive even after the haircut, though coverage is thin with just three firms. Valuation multiples remain negative — the P/E and EV/EBITDA are both deeply in loss-making territory, as expected for a company at this stage — making traditional valuation anchors largely academic. The EPS surprise factor score ranks in the 80th percentile, consistent with a track record of beating lowered estimates.
The institutional register is dominated by concentrated, relatively static holders. Dana Carrera and Craig Kallman each control roughly 8% of shares, both with no reported change as of late 2025. Nantahala Capital Management holds around 7.7%. Vanguard added nearly 69,000 shares as of end-March and Geode added 31,000 in February — small moves, but directionally constructive from passive managers who would not ordinarily be building positions in a micro-cap unless it clears screening thresholds. The last disclosed insider activity was President Steven Nelson buying 40,000 shares at $0.53 in August 2025 — a price well below today's $8.68, though that data is now stale and should not be read as current signal.
The contrast between the March print and today's is the sharpest thing to watch. March delivered -10.5% on the day and -5.4% over five sessions. Today's result carries a larger positive surprise on EPS, a concrete channel partnership announcement, and a stock that is already up roughly 20% on the month. The question the market is now calibrating is whether the announced channel partner converts into revenue in the timeline management described — later this year and into 2027 — or whether the company's history of signing accounts ahead of revenue recognition means the uplift stays on the horizon.
See the live data behind this article on ORTEX.
Open DRIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
